Considering all LAM patients irrespective of LT, those under sirolimus treatment had a median VEGF-D of 610 (486–886) pg/ml compared to 658 (452–1,638) pg/ml in those without treatment (p = 0.457). The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.